The agency is testing a continuous-data-review model that could compress the dead-time between trial phases. The first programs are oncology drugs — but the structural change is relevant to any biomarker-heavy clinical program, including the geroscience trials that anchor the longevity field.
The FDA announced on April 28, 2026 that it will pilot a real-time clinical-trial monitoring program with AstraZeneca and Amgen, reviewing trial data as it accrues rather than evaluating it in batched submissions between phases. The first programs in the pilot are oncology drugs, but the underlying mechanism — continuous review — has implications for any therapeutic area, including the geroscience trials that the longevity-medicine community is increasingly running.
Under the traditional model, a sponsor completes a Phase, packages the data, and submits it to the FDA. The agency reviews; the sponsor waits; the next phase begins. The continuous-review pilot compresses that cycle by letting FDA reviewers see data as it's collected. In principle, that means earlier feedback, faster pivots when something looks off, and shorter waits between phases. The FDA framed it as a way to reduce the dead-time interval between trial phases.
Aging-targeted clinical trials face a structural problem the agency has acknowledged but not solved: aging is not a recognized indication, so trials have to anchor on specific diseases (diabetic eye disease, sarcopenia, mild cognitive impairment, etc.). That forces gerotherapeutic programs into long, conventional Phase 1 → 2 → 3 timelines designed for acute interventions. The dead-time problem is amplified when biomarker endpoints — epigenetic clocks, frailty measures, inflammatory markers — take months to read out.
A continuous-review framework wouldn't change the indication-shaped corset that geroscience operates under, but it would change the speed at which biomarker signals get interpreted. That could materially shorten the path for programs targeting NLRP3, mTOR, senolytic clearance, and similar mechanisms — programs that are increasingly using biomarker-of-aging endpoints rather than hard-clinical ones.
The FDA is testing a faster, continuous-review model for clinical trials, starting in oncology. If it scales, it could meaningfully compress the timeline for geroscience programs that rely on biomarker readouts — though it won't, on its own, change the FDA's reluctance to treat aging itself as an indication.
The pilot's success criteria, which the FDA hasn't fully disclosed publicly, will tell us whether this is a sustained policy shift or a one-off. If the agency reports time-to-decision improvements without compromising safety review quality, expect the model to expand. If it bottlenecks on reviewer capacity, it stays small. Either way, sponsors running geroscience trials should be talking to the agency now about whether their biomarker-heavy programs are candidates.